NanoViricides is a development-stage company engaged in creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates is designed for the specific purpose of attacking and dismantling enveloped virus particles. NanoViricides is developing drugs against various viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes (HSV), viral diseases of the eye, Ebola virus and others. For more information, visit the company’s Web site at www.nanoviricides.com.

The 6th Annual OneMedForum is a gathering of leading investors and management of some of the most promising emerging life science companies in Asia and North America. Through panels, workshops and up-close programming with top industry leaders, attendees explore strategies for company growth finance with healthcare investors looking for outsized returns. For more information, please visit www.onemedforum.com.

Let us hear your thoughts below: